PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)--Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced it has entered into definitive agreements with investors to purchase an aggregate of $8,000,000 in units, consisting of ordinary shares and warrants, in a private placement. The closing is expected to occur on or about October 16, 2015 and is subject to the satisfaction of customary closing conditions.
Help employers find you! Check out all the jobs and post your resume.
